Scientific paper

Study on the Synthesis, Characterization and Bioactivities of 3-Methyl-9’-fluorenespiro-5-hydantoin

Petja Marinova,1,ag Marin Marinov,2 Maria Kazakova,3 Yana Feodorova,3 Alexander Slavchev,4 Denica Blazheva,4 Danail Georgiev,1,b Plamen Penchev,1,c Victoria Sarafian3 and Neyko Stoyanov5

1a University of Plovdiv, Faculty of Chemistry, Department of General and Inorganic Chemistry with Methodology of Chemistry Education, 4000 Plovdiv, 24 “Tzar Asen” St, Bulgaria
1b University of Plovdiv, Faculty of Biology, Department of Biochemistry and Microbiology, 4000 Plovdiv, 24 “Tzar Asen” St, Bulgaria
1c University of Plovdiv, Faculty of Chemistry, Department of Analytical Chemistry and Computer Chemistry, 4000 Plovdiv, 24 “Tzar Asen” St, Bulgaria
2 Agricultural University - Plovdiv, Faculty of Plant Protection and Agroecology, Department of General Chemistry, 4000 Plovdiv, 12 “Mendeleev” Blvd, Bulgaria
3 Medical University - Plovdiv, Department of Medical Biology, 4002 Plovdiv, 15 A “V. Aprilov” Blvd, Bulgaria
4 University of Food Technologies, Department of Microbiology, 4002 Plovdiv, 26 “Maritza” Blvd, Bulgaria
5 University of Ruse - Razgrad Branch, Department of Chemistry and Chemical Technology, 7200 Razgrad, 47 “Aprilsko Vastanie” St, Bulgaria

* Corresponding author: E-mail: petia_marinova@abv.bg
Received: 07-04-2015

Abstract

This work describes a method for synthesis, as well as in vitro antiproliferative and antibacterial investigation of 3-methyl-9’-fluorenespiro-5-hydantoin. The structure of the substituted fluorenylspirohydantoin derivative was verified by UV-Vis, FT-IR, Raman, 1H NMR and 13C NMR spectroscopy, and by using a combination of 2D NMR experiments, which included 1H-1H COSY, HMQC and HMBC sequences. The geometry of the compound was optimized by the B3LYP density functional with 6-31G(d) basis set and the 1H and 13C NMR spectra were predicted with the HF/6-31G(d) calculations at the optimized geometry. The anticancer activity of the 3-methyl-9’-fluorenespiro-5-hydantoin was determined in suspension cell lines originating from tumors in humans (WERI-Rb-1). The cytotoxic effect was evaluated by WST-assay (Roche Applied Science). The antimicrobial effect of the compound against Gram-negative, Gram-positive bacteria and the yeast Candida albicans was investigated.

Keywords: 3-methyl-9’-fluorenespiro-5-hydantoin; NMR spectra; cytotoxic activity; antimicrobial effect

1. Introduction

Hydantoins, or 2,4-imidazolidinediones are compounds of considerable interest both from a chemical and biological point of view.1 Several compounds of this class have shown a pharmaceutically useful activity that led in some cases to clinical applications. In particular, 5-substituted and 5,5-disubstituted hydantoins are important medicinal compounds: phenytoin, or 5,5-diphenylhydantoin, is widely used as an anticonvulsant agent, for the treatment of epilepsy, and as a cardiac antiarrhythmic agents.2,3 Among the medicinally useful properties exhibited by other 5-substituted hydantoins, at least their antidepressant and antiviral activities, the inhibition of platelet aggrega-
tion as well as human aldose reductase and human leu-
kocyte elastase inhibition are worth mentioning. A num-
ber of other biological activities of hydantoin derivatives
are known, including possible uses as herbicides, fung-
cides and insecticides.

Lee et al. presented the molecular modeling of six
structurally diverse ARIs (aldose reductase inhibitors), be-
ning carried out at the active site of aldose reductase to pro-
be the charge interactions between the ionizable group
(e.g. carboxylate or hydantoin) of the ARIs and the posi-
tively charged His 110. An attempt was also made to cor-
relate the binding mode of these structurally diverse in-
hibitors to observed inhibitory activity. Palm et al. investi-
gated the influence of diabetes-induced changes in oxy-
gen tension and consumption in relation to regional renal
metabolism in rats. In the second set of experiments, the
putative role of the polyl pathway for hyperglycaemia-
duced alterations in renal metabolism was studied. Su-
giyama et al. reported a method for the in vitro isolation of
a non-covalent complex formed in solution by the interac-
tion of human muscle or rat lens aldose reductase with ei-
ther NADP* or NADPH and the aldose reductase inhibitors
tolrestat, AL1576 (2,7-difluorospirofluorene-9,5'-imida-
zolidine-2',4'-dione), or ponalrestat. Kato et al. investi-
gated the effects of novel aldose reductase inhibitors, M16209 (1-(3-bromobenzol[b]furan-2-ylsulfonyl)hydan-
toin) and M16287 (1-(3-chlorobenzol[b]furan-2-ylsul-
fonyl)hydantoin), on neuropathy in streptozotocin-induced
(STZ) diabetic rats. The effect of a single oral admin-
istration of M16209, a novel aldose reductase inhibitor,
on serum glucose was investigated by Nakayama et al.
The group of Nakayama investigated the stimulatory ef-
teffects of M16209 on insulin secretion using isolated, per-
fused pancreases in rats. M16209 showed no appreci-
able effect on ATP-sensitive K+-channels in pancreatic β-
cells. Two potent aldose reductase inhibitors, 1-[2,5-
dichlorophenyl]sulfonyl]hydantoin (Di-CIPSH) and 1-
[β-naphthyl]sulfony]hydantoin (β-NSH), were tested for usef
ess in the treatment of diabetic and galactose-
emic complications in animal experiments.

Sorbitol formation from glucose, catalyzed by the
enzyme aldose reductase, is believed to play a role in the
development of certain chronic complications of diabetes
mellitus. Spirohydantoins derived from five- and six-mem-
bered ketones fused to an aromatic ring or ring system in-
hibit aldose reductase isolated from calf lens. In vivo these
compounds are potent inhibitors of sorbitol formation in
sciatic nerves of streptozotocinized rats. Optimum in vivo
activity is reached in spirohydantoins derived from 6-halo-
genated 2,3-dihydro-4H-1-benzopyran-4-ones (4-chroma-
nones). In 2,4-dihydro-6-fluorospiro[4H-1-benzopyran-
4,4'-imidazolidine]-2',5'-dione, the activity resides exclu-
sively in the 4S isomer, compound 115 (CP-45,634,
USAN: sorbinil). This compound is currently being used
to test, in humans, the value of aldose reductase inhibitors
in the therapy of diabetic complications. A series of 27

hydantoins was prepared and tested as antitumor agents.
These were variously substituted at the 5 position but with
special emphasis on the substituents (chloro, acetyl, chlo-
roacetyl, and methyl) at the 1 and/or 3 positions. The most
active compound was 5,5-bist(4-chlorophenyl)-1,3-dichlo-
rohydantoin with a T/C value of 190% against P-388
lymphocytic leukemia in mice.

Hydantoinases are valuable enzymes for the produc-
tion of optically pure D- and L-amino acids. They catalyze
the reversible hydrolytic ring cleavage of hydantoin or
5-monosubstituted hydantoins and therefore are classified
in the EC-nomenclature as cyclic amidases C 3.5.2. Hydantoinases
have been classified into D-, L-, unsselective or ATP-requiring enzymes due to their substrate specificity,
stereoselectivity and cofactor dependency. From recent
findings based on protein sequence data all hydantoin cleav-
ing enzymes, with the exception of the ATP-dependent
N-methylhydantoinases, belong to a protein superfamily
of amidohydrolases related to urease and seem to have
emerged from a common ancestor in a divergent evolution.

A D-specific hydantoinase has been purified to homoge-
neity from Arthrobacter crystallloploites DSM 20117 with
a yield of 5% related to the crude extract. The group of
Yamada was the first to study intensively the D-selective
cleavage of 5-monosubstituted hydantoins in microorgan-
isms. They postulated the identity of microbial D-hydan-
toinases with dihydropyrimidinases and proved this hypot-
thesis for the enzyme from Pseudomonas striata. In the
meantime, several publications described various similar
D-selective microbial hydantoinases from microorganisms,
such as Pseudomonas fluorescens DSM 84, Pseudomo-
unas sp. AJ11220, Agrobacterium sp. IP-1 671, several Bacillus spp. and even from anaerobic microorgan-
isms. However, recently a hydantoinase from Agrobac-
terium was identified which exhibits no dihydropyrimidase
activity. DL-5-Monosubstituted hydantoins are converted
to D-amino acids via N-carbamoyl-D-amino acids by some
bacteria. Takahashi et al. revealed that in Pseudo-
monas putida (P. striata) IFO 12996, D-hydantoinase is
identical with dihdyropyrimidinase, which catalyzes the
cyclic ureide-hydrolyzing step of the reductive degradat-
on of pyrimidine bases. The same results were obtained for oth-
er Pseudomonas species, Comamonas species, Bac-
illus species, Arthrobacter species, Agrobacterium speci-
es, and rat liver. Various 5-chloroaryliden-2-amino
substituted derivatives of imidazole-4-one were synthe-
sized and evaluated for their activity in vitro against Myco-
bacterium tuberculosis and other type strains of bacteria
and fungi. 2-Chloro- and 2,4-dichlorobenzylidene substi-
tuted hydantoins exhibited antimycobacterial effect. The
antimiotic effect of the investigated hydantoins was also
examined. In the course of structure-activity relationship
(SAR) studies and to explore the antiproliferative effect as-
associated with the hydantoin framework, several diversely
substituted diazaspiro hydantoins were synthesized. Va-
riation in the functional group at N-terminal of the hydan-
toin ring and coupling of different substituted aromatic acids in 4-aminocyclohexane ring led to three sets of compounds. The antiproliferative effect of the compounds was evaluated in vitro using the MTT test against one normal cell line (NDF-103 skin fibroblast cells) and four human cancer cell lines (MCF-7 breast carcinoma cell line, HepG-2 hepatocellular carcinoma cell line, HeLa cervix carcinoma cell line and HT-29 colon carcinoma cell line) for the time period of 24 h. Among the series, some compounds exhibited interesting growth inhibitory effects against all four cell lines. The SAR studies revealed that the substitution at N-terminal in hydantoin ring played a key role in the antiproliferative activity.

Especially, it is important to note that the study of (9′-fluorene)-spiro-5-hydantoin/spiro-(fluorene-9,4′-imidazolidine)-2′,5′-dione and its derivatives is mainly determined from the point of their biological activity. Such compounds are known as aldose reductase inhibitors and some of them have antitumor activity.52,53 In our previous works we reported several studies about different methods for synthesis of monothio and dithio-analogues of (9′-fluorene)-spiro-5-hydantoin.54–56 Furthermore, a method for (4′,5′-diaza-9′-fluorene)-spiro-5-hydantoin synthesis has been described.57 Fluorenylspirohydantoins have a good ability to coordinate metal ions. Copper(II) and nickel(II) complexes of (9′-fluorene)-spiro-5-dithiohydantoin,58 as well as platinum(II) complexes of (9′-fluorene)-spiro-5-hydantoin and (9′-fluorene)-spiro-5-(2-thiohydantoin)59 have been described in this aspect. Moreover, we reported studies about synthesis, cytotoxicity and antibacterial activity of some fluorineylspirohydantoin derivatives60–62 and their platinum(II) complexes.50 Recently, we discussed the synthesis, characterization and quantum chemical investigation of new Pt(II) complexes of cyclohexanespiro-5-(2-thiohydantoin) and cycloheptanespiro-5-(2-thiohydantoin).63 In our previous works we reported a method for synthesis, cytotoxicity and antibacterial activity of 3-amino-9′-fluorenespiro-5-hydantoin.64

On the other hand, compounds containing fluorene ring have been proved as organic light emitting diodes (OLED) having application in the practice.64 Although hydantoin compounds are investigated extensively, there are not many reports on their anticancer activity.

For this reason, the goal of the present paper is to describe a method for synthesis of 3-methyl-9′-fluorenespiro-5-hydantoin, its structural elucidation and biological properties (its cytotoxic and antimicrobial effects).

2. Experimental

2.1. Instrumentation and Methods

All chemicals used were purchased from Merck and Sigma-Aldrich. UV/Vis spectra was measured on a Lambda 9 Perkin-Elmer UV/Vis/NIR Spectrophotometer from 200 nm to 1000 nm. The IR spectrum of 3-methyl-9′-fluorenespiro-5-hydantoin was obtained as KBr pellet on a Bruker FT-IR VERTEX 70 Spectrometer from 4000 cm$^{-1}$ to 400 cm$^{-1}$ at resolution 2 cm$^{-1}$ with 25 scans. The Raman spectrum of the obtained product (the stirred crystals placed in aluminium disc) was measured on a RAM II (Buker Optics) with a focused laser beam of 200 mW power of Nd:YAG laser (1064 nm) from 4000 cm$^{-1}$ to 400 cm$^{-1}$ at resolution 2 cm$^{-1}$ with 25 scans. The NMR spectra were taken on a Bruker Avance II+ 600 MHz NMR spectrometer operating at 600.130 and 150.903 MHz for $^1$H and $^{13}$C, respectively, using the standard Bruker software. Chemical shifts were referenced to tetramethylsilane (TMS). Measurements were carried out at ambient temperature.

2.2. Synthesis of 3-Methyl-9′-fluorenespiro-5-hydantoin (2)

The initial 9′-fluorenespiro-5-hydantoin (1) (12.5 g, 0.05 mol) was dissolved in water solution of NaOH (2.5 g in 50 mL of water) and (CH$_3$)$_2$SO$_4$ (8 g, 0.063 mol) was added for 5 minutes at 40 °C (Scheme 1). The reaction mixture was stirred for 10 min at room temperature and was left overnight. The crystalline product 2 obtained was filtered off and recrystallized from methanol. Yield: 10.30 g (78%); m.p.: 227–228 °C; $R_t$ = 0.59 (ethyl acetate : petroleum ether = 1 : 2).

![Scheme 1. Synthesis of 3-methyl-9′-fluorenespiro-5-hydantoin (2)](image)

The spectral data of 2: UV (EtOH) $\lambda_{\text{max}}$ = 306, 271, 235, 228, 210 nm. IR (KBr): $\nu$ 3461, 3232 ($^1$N–H), 3058–3041 (CH, arom.), 2949 (CH$_3$), 2814 (CH$_3$), 1771 (C4=O), 1607, 1585, 1490, 1454 (CH$_3$), 1390 (CH$_3$), 1294, 1237, 1211, 1153, 1129, 1111, 1064 (C–O), 1042, 1033, 1020, 982, 951, 922, 883, 874, 785, 772, 756, 745, 713, 681, 658, 621, 599, 499, 460, 422, 402 cm$^{-1}$. Raman: $\nu$ 3058 (CH$_3$), 3003 (CH$_3$), 2949 (CH$_3$), 2588, 1771 (C$^4$=O), 1607, 1585, 1452 (CH$_3$), 1390 (CH$_3$), 1294, 1237, 1211, 1153, 1129, 1111, 1064 (C–O), 1042, 1033, 1020, 982, 951, 922, 883, 874, 785, 772, 756, 745, 713, 681, 658, 621, 599, 499, 460, 422, 402 cm$^{-1}$. The spectral data of 1: UV (EtOH) $\lambda_{\text{max}}$ = 306, 271, 235, 228, 210 nm. IR (KBr): $\nu$ 3461, 3232 ($^1$N–H), 3058–3041 (CH, arom.), 2946 (CH$_3$), 2814 (CH$_3$), 1771 (C4=O), 1607, 1585, 1490, 1454 (CH$_3$), 1390 (CH$_3$), 1294, 1237, 1211, 1153, 1129, 1111, 1064 (C–O), 1042, 1033, 1020, 982, 951, 922, 883, 874, 785, 772, 756, 745, 713, 681, 658, 621, 599, 499, 460, 422, 402 cm$^{-1}$. Raman: $\nu$ 3058 (CH$_3$), 3003 (CH$_3$), 2949 (CH$_3$), 2588, 1771 (C$^4$=O), 1607, 1585, 1452 (CH$_3$), 1390 (CH$_3$), 1294, 1237, 1211, 1153, 1129, 1111, 1064 (C–O), 1042, 1033, 1020, 982, 951, 922, 883, 874, 785, 772, 756, 745, 713, 681, 658, 621, 599, 499, 460, 422, 402 cm$^{-1}$.

2.3. WST-1 Cell Proliferation Assay

The cytotoxic effect of compound 2 was assessed on a suspension cell line using WST-1 assay (Cat. No11

Marinova et al.: Study on the Synthesis, Characterization and Bioactivities ...
644 807 001, Roche). The suspension retinoblastoma cells (WERI-Rb1, ATCC-HTB-169) were cultured in RPMI 1640 medium, containing 10% FCS, 100 μg/mL streptomycin and 100 units/mL penicillin. Cells were cultured at 37 °C in a humidified atmosphere containing 5% CO₂. The compound was first dissolved in DMSO and then diluted in the respective culture medium. The concentration of DMSO in the wells did not exceed 1%. Cells were seeded in triplicates in 96-well flat-bottom plates at a density of 6.5 × 10⁴ cells/well (WERI-Rb1). After a cultivation period of 24 h, the compound was added at a concentration 100 μM on WERI-Rb1 cells and incubated for 24, 48 and 72 h, respectively. WST-1 was added to the cells at these time points and incubated for 4 h. After the incubation period the absorbance was measured using a microplate ELISA SUNRISE reader at a wavelength of 450 nm with a reference filter at 620 nm. The percentage of viable cells was calculated as a ratio of the OD value of the sample to the OD value of the control. The data are presented as mean ± standard deviation of the mean.

2.4. Antimicrobial Assay

The antimicrobial activity of 2 against Gram-positive bacteria – *Staphylococcus aureus* ATCC 25923 and *Bacillus subtilis*, Gram-negative bacteria – *Escherichia coli* ATCC 25922, *Salmonella enterica subsp enterica* ATCC BAA-2162, *Pseudomonas aeruginosa* ATCC 9027 and the yeasts *Candida albicans* ATCC 10231 was investigated using the agar diffusion method. Melted PCA (Scharlau) nutrient medium was inoculated through the addition of 1 mL of microbial suspension (1 × 10^10 CFU/mL for the bacteria and 1 × 10^8 CFU/mL for the yeast) and was poured in Petri dishes, 20 mL in each dish. Wells with 7 mm diameter were made in the solidified and cooled agar medium. 50 μL of the tested substance solution (5.38 mg/mL in 15% DMSO) was pipetted into the wells. The current concentrations of the test microorganisms in the suspensions were as follow: *S. aureus* 3.4 × 10^6; *Bacillus subtilis* 2.21 × 10^6; *E. coli* 1.02 × 10^6; *S. enterica subsp enterica* 1.12 × 10^6; *P. aeruginosa* 1.07 × 10^6; *C. albicans* 4 × 10^5 cfu/mL. The Petri dishes were incubated at 37 °C for 24–48 h. The inhibition zone was measured. Zones with diameter more than 7 mm were considered zones of inhibition.

2.5. Computational Details

To additionally verify the proposed assignments, quantum chemistry calculations were performed by using the Gaussian 98, Revision A.7.66 For the geometry optimization the B3LYP density functional with 6-31G(d) basis set was used and for the ¹H and ¹³C NMR spectra prediction the HF/6-31G(d) calculations were carried out at the optimized geometry.

3. Results and Discussion

A synthesis procedure for 9’-fluorenespiro-5-hydantoin methylation with diazomethane has already been described.66 Here we present a new method for 3-methyl-9’-fluorenespiro-5-hydantoin (2) preparation. The method discussed here is based on the reaction of 9’-fluorenespiro-5-hydantoin with dimethyl sulfate. The target product was obtained with high yield (78%) and showed m.p. 227–228 °C. The synthesis of 2 was carried as shown in Scheme 1. The structure of 2 was determined by UV-Vis, FT-IR, Raman, ¹H NMR and ¹³C NMR spectroscopy. Maxima in the UV/Vis spectrum of the 2 were observed at 306, 271, 235, 228, 210 nm. The IR band at 3232 cm⁻¹ of 2 that was observed may refer to the stretching vibration of the N–H group of the hydantoin ring. The vibrational (N¹–H) stretching mode did not appear in the Raman spectrum. In the IR spectrum of the 2 the bands at 1775 cm⁻¹ and 1717 cm⁻¹ can be attributed to stretching vibrations of the two C=O groups of the hydantoin ring. In the Raman spectrum of 2 the one of the two C=O groups appeared at 1771 cm⁻¹. The other vibrational (C=O) stretching mode did not appear in the Raman spectrum. Several bands in the IR spectrum (3058, 3041 cm⁻¹) and in the Raman spectrum (3058, 3003 cm⁻¹) were for stretching vibrations of CH in fluorene moiety. In the IR spectrum of the 2 the bands at 2946 cm⁻¹ and 2814 cm⁻¹ can be attributed to stretching vibrations of the CH group. In Raman spectrum of 2 the former vibration appeared at 2949 cm⁻¹.

The ¹H-broadband-decoupled ¹³C NMR spectrum of 2 showed 10 signals: 6 pairs of atoms were magnetically equivalent. The two signals with the highest chemical shift in ¹³C NMR spectrum, 173.06 and 157.58 ppm, were for the carbonyl groups (C²=O) and (C²=O). The signals at 71.54 and 25.49 ppm were for the spiro-carbon and methyl group. The structure of multiplets and coupling constants in ¹H NMR spectrum were consistent with the structure of 2. The assignment of signal at 71.54 to the spiro carbon, C-9’, was supported also by an HMBC correlation of HN with it (δH 8.87–δC 71.54). There was also an HMBC correlation δH 7.47–δC 71.54 which points out that this δH is for H-1’⁸. This inference and the COSY correlations allow to unambiguously assign all proton signals. As only the meta (vicinal) coupling (JCH) in benzene rings is usually resolved,67 the assignments of the quaternary carbons, C-1’a’, C-4’a’, C-5’a and C-8’a’, can be made (Table 1).

The effect of the compound 2 on the proliferation of WERI-Rb1 cells after 24 and 72 h of treatment is presented in Fig. 1. The results from the cytotoxicity assay on the human WERI-Rb-1 cell line showed that the product 2 reduced the number of tumor cells by around 2% after 24 h. It showed a significant cytotoxic effect after 72 h of treatment when cell vitality decreased by 80%.

The results for the antimicrobial activity of 2 are presented in Table 2. Compound 2 showed strong antimi-
Table 1. $^1$H and $^{13}$C NMR spectral data and $^1$H- $^1$H COSY and HMBC correlations for 2 (600.13 MHz ($^1$H) and 150.903 MHz ($^{13}$C))$^{a,b}$

| Atom | $\delta$ ($^{13}$C) ppm | DEPT$^b$ | $\delta$ ($^1$H) ppm | Multiplicity (J, Hz) | $^1$H-$^1$H COSY$^c$ | HMBC$^c$ |
|------|---------------------|----------|---------------------|---------------------|---------------------|---------|
| 1 (NH) | – | – | 8.87 | s | – | 2, 4, 9$^*$ |
| 2 (C=O) | 157.58 | C | – | – | – | – |
| 4 (C=O) | 173.06 | C | – | – | – | – |
| 1’ / 8’ | 124.29 | CH | 7.47 | d (7.9) | 2’ | 3’, 4a’, 9’, 2$^*d$ |
| 1a’ / 8a’ | 143.13 | C | – | – | – | – |
| 2’ / 7’ | 128.76 | CH | 7.35 | td (7.5, 0.9) | 1’, 3’ | 1a’, 3$^{vd}$, 4’, 9$^{vd}$ |
| 3’ / 6’ | 130.36 | CH | 7.50 | dd (7.5, 0.9) | 2’, 4’ | 1’, 2$^{rd}$, 4a’ |
| 4’ / 5’ | 121.20 | CH | 7.90 | dt (7.5, n/a) | 3’ | 1a’, 2’, 5a’ |
| 4a’ / 5a’ | 141.16 | C | – | – | – | – |
| 5 (9’$^*$) | 71.54 | C | – | – | – | – |
| 25.49 | CH$_3$ | 3.00 | s | – | – | 2, 4 |

$^a$ In DMSO-$d_6$ solution. All these assignments were in agreement with COSY, HMQC and HMBC spectra. $^b$ Abbreviations: DEPT, Distortionless Enhancement by Polarization Transfer spectrum; $^1$H-$^1$H COSY – proton-proton homonuclear correlation spectrum; HMQC, Heteronuclear Multiple Quantum Correlation experiment; HMBC, Long range $^1$H-$^{13}$C Heteronuclear Multiple Bond Correlation experiment. $^c$ For brevity these correlations are given only in one of the benzene rings. $^d$ These correlations are weak.

Fig. 1. Effect of the compound 2 (100 μM) on the proliferation of WERI-Rb1 after 24 h and 72 h of treatment

Table 2. Antimicrobial activity of 3-methyl-9'-fluorenespiro-5-hydantoin (2)

| Run | Test microorganism | Viable cells count in the nutrient medium, cfu/mL | Inhibition zone, mm |
|-----|-------------------|-----------------------------------------------|-------------------|
| 1   | *Escherichia coli* ATCC 25922 | $1.02 \times 10^9$ | – |
| 2   | *Salmonella enterica subsp enterica* ATCC BAA-2162 | $1.12 \times 10^9$ | – |
| 3   | *Bacillus subtilis* | $2.21 \times 10^9$ | 15/15$^a$ |
| 4   | *Staphylococcus aureus* ATCC 25923 | $3.4 \times 10^9$ | 9/9 |
| 5   | *Pseudomonas aeruginosa* ATCC 9027 | $1.07 \times 10^9$ | 9/9 |
| 6   | *Candida albicans* ATCC 10231 | $4 \times 10^6$ | – |

Well diameter: 6 mm
$^a$ Inhibition zone with single cell colonies.

4. Conclusions

The method for synthesis of 3-methyl-9'-fluorenespiro-5-hydantoin (2) was presented. The structure of the obtained product 2 was determined by UV-Vis, FT-IR, $^1$H, $^{13}$C NMR and Raman spectroscopy, as well as by means of one- and two-dimensional NMR techniques, including HMQC, $^1$H-$^1$H COSY, and HMBC spectra. The preliminary results of our study showed that the compound could serve as a potential anticancer agent. Further investigations are needed to elucidate the exact mechanisms of this action and to exclude any cytotoxic effect on normal cells. The results for the compound 2 showed...
that it has potential as antimicrobial agent against Gram positive bacteria.

The numbered structure of 2, complete spectral data, with enlarged detailed sections for multiplets and cross peaks in NMR spectra, as well as the archive Gaussian job results are included in Supporting Information.

5. Acknowledgements

This work has been supported by the the National Science Fund of Bulgaria, contract DFNI BO1/0014.

6. References

1. E. Kleinpeter, Struct. Chem. 1997, 8, 161–173.  
   http://dx.doi.org/10.1007/BF02262852

2. B. Bogoch, J. Dreyfus, The Broad Range of Use of Diphenylhydantoin, Dreyfus Medical Foundation, New York, 1970.

3. J. K. Perry, M. E. Newmark, Ann. Intern. Med. 1979, 89, 207–218.

4. H. Sano, S. Mio, J. Kitagawa, M. Shindou, T. Homma, S. Sugai, Tetrahedron, 1995, 51, 12563–12572.  
   http://dx.doi.org/10.1016/0040-4020(95)00810-U

5. H. Sano, S. Mio, M. Hamura, J. Kitagawa, M. Shindou, T. Homma, S. Sugai, Biosci., Biotechnol., Biochem., 1995, 59, 2247–2250.  
   http://dx.doi.org/10.1271/bbb.95.2247

6. H. Ohta, T. Jikihara, K. Wakabayashi, T. Fujita, Pestic. Biochem. Physiol., 1980, 14, 153–160.  
   http://dx.doi.org/10.1016/0048-3575(80)90106-6

7. L. Schröder, W. Stransky, R. Mengel, E. Raddatz, S. Lust, G. Linden, G. Schneider, Herbicidal hydantoins, US Patent Number 4,944,791, date of patent July 31, 1990.

8. W. J. French, Proc. Fla. State Hort. Soc., 1976, 89, 271–273.

9. J. Marton, J. Enisz, S. Hosztafi, T. Timar, J. Agric. Food Chem., 1993, 41, 148–152.  
   http://dx.doi.org/10.1021/jf00025a031

10. M. Marinov, D. Ganchev, P. Marinova, St. Krustev, N. Atanasova, M. Zlateva and N. Stoyanov, Bulg. J. Agric. Sci., 2012, 18, 929–933.

11. D. Ganchev, M. Marinov, M. Zlateva, R. Prodanova, A. Nikolov, S. Krustev, N. Stoyanov, University of Ruse “Angel Kanchev” Proceedings, 2013, 52 (10.2), 16–20.

12. M. Marinov, D. H. Ganchev, P. E. Marinova, A. S. Nikolov, R. Y. Prodanova, S. V. Krustev, M. R. Zlateva, N. M. Stoyanov, J. Sci. Appl. Res., 2013, 4, 171–177.

13. D. I. Atanasova, D. H. Ganchev, P. E. Marinova, N. M. Stoyanov, R. Y. Prodanova, S. V. Krustev, M. N. Marinov, J. Int. Sci. Pub.: Agric. & Food, 2014, 2, 338–345.

14. D. Ganchev, D. Atanasova, P. Marinova, N. Stoyanov, R. Prodanova, M. Marinov, Agric. Univ. – Plovdiv, 2014, LVIII, 203–209.

15. D. Atanasova, D. Ganchev, P. Marinova, N. Stoyanov, R. Prodanova, M. Marinov, Agric. Univ. – Plovdiv, 2014, LVIII, 211–218.

16. Y. S. Lee, Z. Chen, P. Kador, Bioorg. Med. Chem. 1998, 6, 1811–1819.  
   http://dx.doi.org/10.1016/S0968-0896(98)00139-4

17. F. Palm, P. Hansell, G. Ronquist, A. Waldenström, P. Liss, P.-O. Carlsson, Diabetologia 2004, 47, 1223–1231.  
   http://dx.doi.org/10.1007/s00125-004-1434-3

18. K. Sugiyama, Z. Chen, Y. S. Lee, P. F. Kador, Biochem. Pharmacol., 2000, 59, 329–336.  
   http://dx.doi.org/10.1016/S0006-2952(99)00332-9

19. K. Kato, N. Nakayama, M. Ohta, N. Murakami, K. Muracami, M. Mizota, I. Miwa, J. Okuda, Eur. J. Pharmacol., 1991, 193, 185–191.  
   http://dx.doi.org/10.1016/0014-2999(91)90035-O

20. K. Nakayama, N. Murakami, M. Ohta, K. Kato, I. Ida, M. Mizota, I. Miwa, J. Okuda, Eur. J. Pharmacol., 1995, 276, 77–83.  
   http://dx.doi.org/10.1016/0014-2999(95)00015-D

21. K. Nakayama, N. Murakami, M. Ohta, K. Kato, T. Notsu, M. Mizota, I. Miwa, J. Okuda, Eur. J. Pharmacol., 1995, 276, 85–91.  
   http://dx.doi.org/10.1016/0014-2999(95)00016-E

22. I. Miwa, M. Hirano, M. Kanbara, J. Okuda, Biochem. Pharmacol., 1989, 40, 303–307.  
   http://dx.doi.org/10.1016/0006-2952(90)90692-E

23. R. Sarges, R. C. Schnur, J. L. Bellotière, M. J. Peterson, J. Med. Chem., 1988, 31, 230–243.  
   http://dx.doi.org/10.1021/jm00396a037

24. T. R. Rodgers, M. P. LaMontagne, A. Markovac, A. B. Ash, J. Med. Chem., 1970, 13, 743–747.

25. International Union of Biochemistry, Enzyme Nomenclature, Academic Press, New York, 1992.

26. L. Holm, C. Sander, Proteins 1997, 19, 165–173.  
   http://dx.doi.org/10.1002/prot.340190302

27. O. May, A. Habenicht, R. Mattes, C. Syldatk, M. Siemann, Biol. Chem. 1998, 379, 743–747.

28. M. Siemann, A. Alvarado-Marín, M. Pietzsch, C. Syldatk, J. Mol. Catal. B: Enzym., 1999, 6, 387–397.  
   http://dx.doi.org/10.1016/S1381-1177(98)00137-4

29. H. Yamada, S. Takahashi, Y. Kii, H. J. Kumagai, J. Ferment. Technol. 1978, 56, 484–491.

30. S. Takahashi, Y. Kii, H. Kumagai, H. Yamada, J. Ferment. Technol. 1978, 56, 492–498.

31. A. Morin, W. Hummel, H. Schütte, H. Kula, M.-R. Biotechnol. Appl. Biochem. 1986, 8, 564–574.

32. K. Yokozeki, K. Kubota, Agric. Biol. Chem. 1987, 51, 721–728.  
   http://dx.doi.org/10.1271/bbb1961.51.721

33. K. Yokozeki, S. Nakamori, S. Yamanaka, C. Eguchi, K. Mitsugi, Agric. Biol. Chem. 1987, 51, 715–719.  
   http://dx.doi.org/10.1271/bbb1961.51.715

34. S. M. Runser, P. C. Meyer, Eur. J. Biochem. 1993, 213, 1315–1324.  
   http://dx.doi.org/10.1111/j.1432-1323.1993.tb17883.x

35. S. Runser, F. Ohlery, Biotechnol. Lett. 1990, 12, 259–264.  
   http://dx.doi.org/10.1007/BF01093518

36. T. Ishikawa, Y. Mukohara, K. Watabe, S. Kobayashi, H. Nakamura, Biosci. Biotech. Biochem. 1994, 58, 265–270.  
   http://dx.doi.org/10.1271/bbb.58.265
Povzetek

V tem delu predstavljamo sintoze ter in vitro študijo antiproliferativnega in antibakterijskega delovanja 3-metil-9’-fluorenspiro-5-hidantoina. Strukturo substituiranega fluoreni spiroidantoiniskoga derivata smo potrdili z UV-Vis, FT-IR, Raman, 1H in 13C NMR spektrometri, HMQC in HMBC sekvence. Geometrijo spojine smo računalno optimizirali z B3LYP gostotnostnim funkcionalom.

Marinova et al.: Study on the Synthesis, Characterization and Bioactivities ...